[Effects of PPARgamma agonist on dyslipidemia and atherosclerosis].
Peroxisome proliferator-activated receptor (PPAR) gamma is a nuclear receptor and ligand-activated transcription factor which plays important roles in the control of energy balance. The thiazolidinediones (TZDs), in use as an insulin-sensitizing agent, are well known as the PPARgamma agonist. Recent studies reported that PPARgamma agonists involve in lipid metabolism through regulating genes including lipoprotein lipase, CD36, and ABCA1. Some clinical trials have been shown that TZD decreased serum levels of LDL-cholesterol and triglycerides and increased serum levels of HDL-cholesterol in type 2 diabetes. In addition, activation of PPARgamma is implicated in the regulation of endothelial function, proliferation and migration of vascular smooth muscle cells, and activation of macrophages.
Komatsu
Aiko
A
Department of Cardiovascular and Renal Medicine, Saga University.
Node
Koichi
K
D050197:Atherosclerosis / Q000188:drug therapy*; D006801:Humans; D052439:Lipid Metabolism Disorders / Q000188:drug therapy*; D047495:PPAR gamma / Q000819:agonists*; D045162:Thiazolidinediones / Q000627:therapeutic use*
D047495:PPAR gamma; D045162:Thiazolidinediones